A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
Status:
Recruiting
Trial end date:
2024-01-10
Target enrollment:
Participant gender:
Summary
This clinical trial will investigate the effectiveness and safety of a new active ingredient
(LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by
subcutaneous injection. Some people in the trial will instead receive Dupixent® which is an
approved treatment for moderate to severe AD. Dupixent® is also given by subcutaneous
injection.
The main aim of this clinical trial is to investigate which changes in biomarkers in the skin
are caused by LEO 138559 and Dupixent®.
The trial includes a screening phase of up to 4 weeks, followed by a treatment period of 16
weeks, and a safety follow-up period of 16 weeks.